Skip to main content Back to Top
Advertisement

10/14/2022

Activated Charcoal Oral Suspension

Products Affected - Description

    • Actidose Aqua oral suspension, Padagis, 15 gram/72 mL, tube, NDC 00574-0521-25
    • Actidose Aqua oral suspension, Padagis, 50 gram/240 mL, tube, NDC 00574-0521-76
    • Actidose with Sorbitol oral suspension, Padagis, 25 gram/120 mL, tube, NDC 00574-0520-74
    • Actidose with Sorbitol oral suspension, Padagis, 50 gram/240 mL, tube, NDC 00574-0520-76
    • Insta-Char oral suspension, Vista Pharma, 25 gram/120 mL, bottle, NDC 66689-0202-04
    • Insta-Char oral suspension, Vista Pharma, 50 gram/240 mL, bottle, NDC 66689-0201-08
    • Insta-Char oral suspension, Vista Pharma, 50 gram/240 mL, bottle, NDC 66689-0202-08

Reason for the Shortage

    • Padagis states the reason for the shortage is production delays due to capacity issues.
    • Vista Pharm did not provide a reason for the shortage.

Available Products

    • Actidose Aqua oral suspension, Padagis, 25 gram/120 mL, tube, NDC 00574-0521-74
    • Insta-Char oral suspension, Vista Pharma, 25 gram/120 mL, bottle, NDC 66689-0203-04

Estimated Resupply Dates

    • Padagis has Actidose Aqua oral suspension in 15 gram/72 mL tubes and 50 gram/240 mL tubes on back order and the company estimates a release date in late-November 2022. Actidose with Sorbitol oral suspension in 25 gram/120 mL and 50 gram/240 mL tubes are also on back order and the company estimates a release date in late-November 2022. Actidose Aqua oral suspension in 25 gram/120 mL tubes are available but are expected to go on back order in mid-October 2022.
    • Vista Pharm has Insta-Char 25 gram/120 mL bottles (NDC 66689-0202-04) and 50 gram/240 mL bottles on back order and the company cannot estimate a release date.

Updated

Created October 14, 2022 by Leslie Jensen, PharmD, Drug Information Specialist. © 2022, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.